CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 35 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 16 pages
National Center for Emergin g and Zoonoti c Infectiou s Diseases Mpox Vaccine Work Group Pablo Sanchez MD *he +hio State ,ni-ersity.Na/on0ide Children1s 2ospital Chair, ACIP Mpox Work Group ACIP Meeting February 22, 2023 Mpox – 2istorical Context – – – – – R are, sometimes life-threatening infection Endemic in parts of west and central Africa Caused by monkeypox virus (which is an orthopoxvirus) C lade…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 18 pages
Epidemiology of Mpo x during the Curre nt Outbreak Sascha Ellington, PhD, MSPH Epidemiology Task Force 2022 Multinational Mpox Response Centers for Disease Control and Prevention February 22, 2023 Epidemiology of the Current Outbreak 21 en l, n2022-2023 Spread of Mpox in U.S. • The first U.S. case was confirmed in May 2022. • At first, spread was associated with international…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 26 pages
National Center for Emergin g and Zoonotic Infectious Diseases JYNNEOS Vaccine Safety Monitoring During the 2022 Mpox Outbreak ─ United States Jonathan Duffy, MD, MPH Immunization Safety Office Centers for Disease Control and Prevention Advisory Committee on Immunization Practices February 22, 2023 CDC Mpox vaccine safety data sources Vaccine Adverse Event Reporting System (VAERS) Vaccine Safety Datalink (VSD) V-safe after vaccination health…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 21 pages
National Center for Emerging and Zoonotic Infectious Diseases JYNNEOS Vaccine Effectiveness Anna Chard, PhD, MPH LT, US Public Health Service Vaccine Effectiveness Team Vaccine Task Force 2022 Multinational Mpox Outbreak Response Centers for Disease Control and Prevention Advisory Committee on Immunization Practices February 22, 2023 Background Efficacy of JYNNEOS against mpox has been…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 26 pages
x Information on Mpox vaccine acceptability and uptake from cross- sectional surveys Kevin P . Delaney, PhD, MPH Community Engagement and Vaccine Policy and Implementation Task Force 2022 Multinational Mpox Response Centers for Disease Control and Prevention Advisory Committee on Immunization Practices February 22, 2023 www.cdc.gov/mpo Information from US-based Clinicians Sermo – online community of >1.3 million clinicians Conducted a worldwide survey of physicians July 31-August…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 12 pages
Mpox Vaccine Implementation and Interim Clinical Considerations Rosalind Carter, PhD Vaccine Task Force 2022 Multinational Mpox Response Centers for Disease Control and Prevention Advisory Committee on Immunization Practices February 22, 2023 www.cdc.gov/mpo x Interim Clinical Considerations (ICC) is a living document • Continued emphasis on vaccination : Mpox vaccination should…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 48 pages
National Center for Emerging and Zoonotic Infectious Diseases Evidence to Recommendations Framework: Vaccination with JYNNEOS During Mpox Outbreaks Agam Rao, MD CAPT, US Public Health Service Poxvirus and Rabies Branch Centers for Disease Control and Prevention Advisory Committee on Immunization Practices February 22, 2023 Evidence to Recommendations Framework Evidence to Recommendations (EtR) Framework Structure to describe information…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 3 pages
Seasonal Influenza Vaccines H. Keipp Talbot , MD, MPH Chair, Influenza Work Group Advisory Committee on Immunization Practices February 22, 2023 Influenza Work Group Session Overview
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 7 pages
U.S. Influenza Activity Lisa Grohskopf Advisory Committee on Immunization Practices February 22, 2023 Virologic Surveillance [ \ ] ^ _ ]`[ \ ] ` _ ] a[ \ ] a _ [ \[ \ [ ] _ [[[ \ [ [ _ [ b [ \ [ \_ [ ]c d e f g h d i jf f k f g h l g m n o o p q pf f k r s t u v w x y For more information, contact CDC 1 -800-CDC-INFO (232-4636) TTY: 1-888-232-6348 ww w.cdc.gov Th e findings and conclusions in this report are those of the authors and do not…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 25 pages
nlzation & Respi Interim Influenza Vaccine Effectiveness against Inpatient, Emergency Department, and Outpatient Illness in the 2022-23 season Data from the New Vaccine Surveillance Network (NVSN), Flu and Other Viruses in the Acutely Ill Network (IVY), & VISION Network Samantha Olson MPH, Nathaniel Lewis PhD, & Mark Tenforde MD PhD Advisory Committee on Immunization Practices February 22, 2023 For more information, contact CDC 1…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 15 pages
Marshfield Clinic Research InstituteInterim Estimates of 2022─23 Influenza Vaccine Effectiveness from Two Studies in Wisconsin: A Test -Negative Case- Control Study and a Community Cohort Study ACIP Meeting | February 22, 2023 Huong McLean presenting on behalf of the study team Marshfield Clinic Research Institute received support for this study from CSL Seqirus and CDC (75D30120C09259) Test-negative case- control study 2 •Enrollees: Outpatients aged 6 months –64 years with acute…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 4 pages
National Center for Immunization & Respiratory Diseases Published Estimates of LAIV Effectiveness Lisa Grohskopf Advisory Committee on Immunization Practices February 22, 2023 Update on Published Estimates of LAIV4 Effectiveness: Background LAIV4 not recommended in the U.S. for 2016 -17 and 2017- 18, following observation of poor effectiveness against H1N1pdm09 viruses. Subsequent studies suggested poor replicative fitness of the LAIV4 H1N1pdm09 - l ike vaccine virus, which was subsequently…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 9 pages
Pneumococcal Vaccines Katherine A. Poehling, MD, MPH Pneumococcal Vaccines Work Group Chair Advisory Committee on Immunization Practices February 22, 2023 Pneumococcal Vaccines Work Group ACIP Members • Katherine Poehling (Chair) • Sarah Long Ex Officio Members • Jeffrey Kelman…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 21 pages
National Center for Immunization & Respiratory Diseases Current Epidemiology of Pediatric Pneumococcal Disease, United States Ryan Gierke, MPH Advisory Committee on Immunization Practices Feb 22, 2023 1 Pneumococcal carriage is precursor to pneumococcal disease Noninvasive Disease Invasive Disease More frequent Less frequent Bogaert, Lancet Infect Dis 2004;4:144-54 2 Outline …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 27 pages
Laur a King, MPH Advisor y Committ ee o n Immunizatio n Practices Februar y 22 , 2023 PP PPeeeeddddiiiiaa aattttrrrriiiiccc c oo oouu uuttttpp ppaaaattttii iiee eenn nnttt t AAAARR RRIII I vv vvii iissssii iitttts ss s aa aannnnddd d aa aannnnttttii iibbbbii iioo oott ttiiiic cc c uu uusssseee e aaaatt tttt ttrrrriiiibb bbuu uuttttaa aabb bblllleee e tt tto oo o ss sseeeerrrroooott ttyyyypp ppeeees ss s ii iinnn n hhhhii iigg gghhhhee eerrr r …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 18 pages
20-valent Pneumococcal Conjugate Vaccine (PCV20) Phase 3 in Pediatrics Wendy Watson, MD Global Clinical Program Lead ACIP February 22, 2023 1 PCV20 is Built on the Established Platforms of PCV7 and PCV13 • PCV20 builds on the 20 -year legacy of PCVs and contains PCV13 components + conjugates for 7 additional PCV20 Composition serotypes to broaden disease coverage for pneumococcal disease in children • The 7 additional conjugates were modelled on the PCV13 Pfizer platform •…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 57 pages
Nationa l Center for Immunizatio n & Respirator y Diseases Evidence to Recommendations Framework (Preliminary): Use of 20-valent Pneumococcal Conjugate Vaccine in U.S. Children Miwako Kobayashi, MD, MPH Pneumococcal Vaccines Work Group Advisory Committee on Immunization Practices February 22, 2023 Evidence to Recommendations (EtR) framework …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 9 pages
Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group Sarah S. Long, MD Chair, Maternal/Pediatric RSV Work Group ACIP Meeting June 28, 2024National Center for Immunization and Respiratory Diseases •RSV prevention in infants during their first RSV season (i.e., aged <8 months) -To protect infants in their first season , either maternal RSV vaccination ( Abrysvo , Pfizer), or use of nirsevimab (Beyfortus , Sanofi and AstraZeneca) in the infant is recommended to prevent RSV lower…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 18 pages
Implementation and Uptake of Nirsevimab and Maternal Vaccine Shannon Stokley, DrPH Deputy Director for Science Implementation Immunization Services Division National Center for Immunizations and Respiratory Diseases (NCIRD) June 2024National Center for Immunization and Respiratory Diseases 2023 -2024 Coverage for Nirsevimab and Maternal Vaccination Percent of pregnant persons ages 18 –49 years vaccinated with RSV vaccine overall and by race and ethnicity, Vaccine Safety Datalink •17.8% of…